Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission

<div>Study outline and patient selection. IFX+IFX: IFX was used as monotherapy during both the period of induction and maintenance; EEN+6-MP/MTX: EEN was used as induction therapy, and 6-MP/MTX was used as monotherapy during maintenance therapy.</div>

Gastroenterology Research and Practice

fig2

Figure 2

Figure 2: Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission 